Table of contents
May 2005 Volume 2 No 5
Editorial
Research Highlights
A novel technique effective for caliceal diverticular stones
206Increased warning time in the management of urinary urgency
206Bladder-neck contracture following surgery for benign prostatic hyperplasia
206Immunotherapy reduces incidence of urinary tract infections in women
207Protein profiling of urine in the diagnosis of bladder cancer
207Long-term effects of pelvic nerve-sparing radical surgery
208Scrotal dartos flap wrapping technique reduces complications of hypospadias surgery
208New criteria for surgical treatment of Peyronie's disease
209Predicting a positive bone scan after radical prostatectomy
209Do patient preferences reduce the validity of randomized trials?
21024-hour urinary calcium as a marker for dietary calcium intake
210Alternative splicing of KLF6 associated with increased risk of prostate cancer
211Practice Points
Does pathological stage affect the prognosis for patients with clinically staged T1 renal cell carcinoma?
212Which clinical variables are associated with lymph node metastases in patients with superficial bladder cancer?
214Diagnosis of primary bladder-neck dysfunction in children and adolescents: treatment with 
-adrenergic antagonists
216Can high-dose interleukin-2 be replaced with lower-dose, outpatient regimens for metastatic renal cell carcinoma?
218Is an artificial urinary sphincter more effective than a urethral bulking agent for postprostatectomy incontinence?
220Does antiseptic washout reduce penile prosthesis infection following revision surgery?
222Reviews
Practical approaches to the diagnosis and management of male infertility
226A comprehensive overview of the state-of-the-art in the evaluation and treatment of male infertility, a problem with diverse etiology that affects 10% of couples. Including several simple algorithms to guide the physician's management decisions, this Review takes an evidence-based medicine approach to provide comment on the relevant merit of conservative and assisted-reproduction strategies.
doi:10.1038/ncpuro0166 | Full Text | PDF (1,289K)
Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction
239The management of erectile dysfunction has been transformed since the first oral phosphodiesterase type 5 (PDE-5) inhibitor sildenafil (Viagra®) was approved in the late 1990s. The PDE-5 inhibitors developed subsequently (tadalafil [Cialis®] and vardenafil [Levitra®]) differ in important ways from their predecessor. Here, Alberto Briganti and his colleagues compare and contrast the pharmacokinetics, pharmacodynamics, safety and efficacy of these three drugs.
doi:10.1038/ncpuro0186 | Full Text | PDF (164K)
Management of von Hippel–Lindau-associated kidney cancer
248Up to half of patients with VHL develop malignant renal lesions. Urologists handling these cases are faced with the challenge of optimizing control of often bilateral multifocal tumors while maximizing preservation of kidney function. Robert Grubb and colleagues assess the relative merits of different management strategies, and present the molecular processes underlying VHL that might be targeted by new treatments.
doi:10.1038/ncpuro0179 | Full Text | PDF (438K)
